Treatment of ocular disease

Abstract

Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.

1 - 20 . (canceled) 
     
     
         21 . A method for treating an ocular condition in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a human protein tyrosine phosphatase beta-extracellular domain (HPTPβ-ECD) binding agent, wherein the therapeutically-effective amount of the HPTPβ-ECD binding agent is from about 0.01 mg/kg to about 500 mg/kg by weight of the subject, wherein the HPTPβ-ECD binding agent is a monoclonal antibody or an antigen-binding fragment thereof. 
     
     
         22 . The method of  claim 21 , wherein the HPTPβ-ECD binding agent binds to an FN3 repeat in the HPTPβ-ECD. 
     
     
         23 . The method of  claim 21 , wherein the HPTPβ-ECD binds to a first FN3 repeat in the HPTPβ-ECD. 
     
     
         24 . The method of  claim 21 , wherein the HPTPβ-ECD binding agent inhibits HPTPβ. 
     
     
         25 . The method of  claim 21 , wherein the HPTPβ-ECD binding agent binds to SEQ ID NO.: 4. 
     
     
         26 . The method of  claim 21 , wherein the HPTPβ-ECD binding agent is administered in a composition, wherein the composition comprises a pharmaceutically-acceptable carrier. 
     
     
         27 . The method of  claim 21 , wherein the monoclonal antibody or the antigen-binding fragment thereof is conjugated to a vehicle. 
     
     
         28 . The method of  claim 27 , wherein the vehicle is polyethylene glycol. 
     
     
         29 . The method of  claim 21 , wherein the HPTPβ-ECD binding agent is administered by intraocular injection. 
     
     
         30 . The method of  claim 21 , wherein the HPTPβ-ECD binding agent is administered by subcutaneous injection. 
     
     
         31 . The method of  claim 21 , wherein the HPTPβ-ECD binding agent is administered by intravenous injection. 
     
     
         32 . The method of  claim 21 , wherein the subject is human. 
     
     
         33 . A composition comprising:
 a) a therapeutically-effective amount of a multi-specific antibody; and   b) a carrier,   
       wherein the multi-specific antibody binds to a human protein tyrosine phosphatase beta-extracellular domain (HPTPβ-ECD) in a subject, and wherein the therapeutically-effective amount of the multi-specific antibody is from about 0.01 mg/kg to about 500 mg/kg by weight of the subject.